Abstract 1453P
Background
Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer (LC) treatment. This study aims to describe the trends of ICI in LC treatment.
Methods
We evaluated treatment regimens and clinical outcomes in the use of ICIs for LC in the Netherlands from 2016-2020 using data from the Netherlands Cancer Registry (NCR) on first-line treatments, and performed a secondary analysis using a local cohort within the University Medical Center Groningen (UMCG) containing all-line treatments. Between 2016-2018, the NCR contained mostly data from patients treated in randomized controlled trials (RCTs) as clinical guidelines advised ICIs only in later treatment lines, whilst NCR data from 2018-2020 and from the UMCG from 2016-2020 were mainly collected outside RCTs. Descriptive statistics and annual percentage change (APC) were used to evaluate changes over time. Also, a survival analysis was performed.
Results
The proportion of first-line ICIs in LC treatment increased from 1.1% in 2016 to 54.9% in 2020 in the Netherlands (6816 patients in total, APC=14.5%, p=0.002). In the UMCG, increases were observed in the proportion of any-line ICI-chemotherapy combination (APC=12.4%, p=0.049), patients surviving ≥1 year (APC=5.8%, p<0.001), and partial response as best overall treatment response (APC=9%, p=0.049), whilst NCR data showed no significant changes over the years. NCR median overall survival (OS) was higher in the period 2016-2018 compared to 2019-2020 (83.4 vs 72.7 weeks, p=<0.001), whilst in the UMCG, 2016-2018 showed a lower median OS compared to 2019-2020 (39.3 [95%CI 32.9-48.6] vs 72.4 weeks [95%CI 52.7-87.4]).
Conclusions
The use of ICIs for LC treatment in the Netherlands increased over the years. Survival data showed better response in the use of ICI as any-line treatment in the UMCG from 2019-2020, contrary to data from patients in the NCR. An explanation for this is the inclusion of mainly RCT patients in the NCR data during the early years of ICI use and the recent shift from second to first-line treatment. As new ICI based drugs emerge, updated analyses will be needed using real-world data to evaluate the real benefits of these newly developed treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Mexico’s National Council of Science and Technology (CONACYT) [Grant No. 1074186] European Union’s Horizon 2020 research and innovation program [grant number 875171].
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20